EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry

Cecilia Hindorf, Gerhard Glatting, Carlo Chiesa, Ola Lindén, Glenn Flux

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Introduction The level of administered activity in radionuclide therapy is often limited by haematological toxicity resulting from the absorbed dose delivered to the bone marrow. The purpose of these EANM guidelines is to provide advice to scientists and clinicians on data acquisition and data analysis related to bone-marrow and whole-body dosimetry. Materials and methods The guidelines are divided into sections "Data acquisition" and "Data analysis". The Data acquisition section provides advice on the measurements required for accurate dosimetry including blood samples, quantitative imaging and/or whole-body measurements with a single probe. Issues specific to given radiopharmaceuticals are considered. The Data analysis section provides advice on the calculation of absorbed doses to the whole body and the bone marrow. The total absorbed dose to the bone marrow consists of contributions from activity in the bone marrow itself (self-absorbed dose) and the crossabsorbed dose to the bone marrow from activity in bone, larger organs and the remainder of the body. Conclusion As radionuclide therapy enters an era where patient-specific dosimetry is used to guide treatments, accurate bone-marrow and whole-body dosimetry will become an essential element of treatment planning. We hope that these guidelines will provide a basis for the optimization and standardization of the treatment of cancer with radiopharmaceuticals, which will facilitate single-and multi-centre radionuclide therapy studies.

Original languageEnglish
Pages (from-to)1238-1250
Number of pages13
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume37
Issue number6
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Bone Marrow
Guidelines
Radioisotopes
Radiopharmaceuticals
Therapeutics
Whole Body Imaging
Bone and Bones
Neoplasms

Keywords

  • Bone marrow
  • Internal dosimetry
  • Radionuclide therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry. / Hindorf, Cecilia; Glatting, Gerhard; Chiesa, Carlo; Lindén, Ola; Flux, Glenn.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, No. 6, 06.2010, p. 1238-1250.

Research output: Contribution to journalArticle

Hindorf, Cecilia ; Glatting, Gerhard ; Chiesa, Carlo ; Lindén, Ola ; Flux, Glenn. / EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry. In: European Journal of Nuclear Medicine and Molecular Imaging. 2010 ; Vol. 37, No. 6. pp. 1238-1250.
@article{65962d4f02224182a0d8e3fcade7b65f,
title = "EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry",
abstract = "Introduction The level of administered activity in radionuclide therapy is often limited by haematological toxicity resulting from the absorbed dose delivered to the bone marrow. The purpose of these EANM guidelines is to provide advice to scientists and clinicians on data acquisition and data analysis related to bone-marrow and whole-body dosimetry. Materials and methods The guidelines are divided into sections {"}Data acquisition{"} and {"}Data analysis{"}. The Data acquisition section provides advice on the measurements required for accurate dosimetry including blood samples, quantitative imaging and/or whole-body measurements with a single probe. Issues specific to given radiopharmaceuticals are considered. The Data analysis section provides advice on the calculation of absorbed doses to the whole body and the bone marrow. The total absorbed dose to the bone marrow consists of contributions from activity in the bone marrow itself (self-absorbed dose) and the crossabsorbed dose to the bone marrow from activity in bone, larger organs and the remainder of the body. Conclusion As radionuclide therapy enters an era where patient-specific dosimetry is used to guide treatments, accurate bone-marrow and whole-body dosimetry will become an essential element of treatment planning. We hope that these guidelines will provide a basis for the optimization and standardization of the treatment of cancer with radiopharmaceuticals, which will facilitate single-and multi-centre radionuclide therapy studies.",
keywords = "Bone marrow, Internal dosimetry, Radionuclide therapy",
author = "Cecilia Hindorf and Gerhard Glatting and Carlo Chiesa and Ola Lind{\'e}n and Glenn Flux",
year = "2010",
month = "6",
doi = "10.1007/s00259-010-1422-4",
language = "English",
volume = "37",
pages = "1238--1250",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "6",

}

TY - JOUR

T1 - EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry

AU - Hindorf, Cecilia

AU - Glatting, Gerhard

AU - Chiesa, Carlo

AU - Lindén, Ola

AU - Flux, Glenn

PY - 2010/6

Y1 - 2010/6

N2 - Introduction The level of administered activity in radionuclide therapy is often limited by haematological toxicity resulting from the absorbed dose delivered to the bone marrow. The purpose of these EANM guidelines is to provide advice to scientists and clinicians on data acquisition and data analysis related to bone-marrow and whole-body dosimetry. Materials and methods The guidelines are divided into sections "Data acquisition" and "Data analysis". The Data acquisition section provides advice on the measurements required for accurate dosimetry including blood samples, quantitative imaging and/or whole-body measurements with a single probe. Issues specific to given radiopharmaceuticals are considered. The Data analysis section provides advice on the calculation of absorbed doses to the whole body and the bone marrow. The total absorbed dose to the bone marrow consists of contributions from activity in the bone marrow itself (self-absorbed dose) and the crossabsorbed dose to the bone marrow from activity in bone, larger organs and the remainder of the body. Conclusion As radionuclide therapy enters an era where patient-specific dosimetry is used to guide treatments, accurate bone-marrow and whole-body dosimetry will become an essential element of treatment planning. We hope that these guidelines will provide a basis for the optimization and standardization of the treatment of cancer with radiopharmaceuticals, which will facilitate single-and multi-centre radionuclide therapy studies.

AB - Introduction The level of administered activity in radionuclide therapy is often limited by haematological toxicity resulting from the absorbed dose delivered to the bone marrow. The purpose of these EANM guidelines is to provide advice to scientists and clinicians on data acquisition and data analysis related to bone-marrow and whole-body dosimetry. Materials and methods The guidelines are divided into sections "Data acquisition" and "Data analysis". The Data acquisition section provides advice on the measurements required for accurate dosimetry including blood samples, quantitative imaging and/or whole-body measurements with a single probe. Issues specific to given radiopharmaceuticals are considered. The Data analysis section provides advice on the calculation of absorbed doses to the whole body and the bone marrow. The total absorbed dose to the bone marrow consists of contributions from activity in the bone marrow itself (self-absorbed dose) and the crossabsorbed dose to the bone marrow from activity in bone, larger organs and the remainder of the body. Conclusion As radionuclide therapy enters an era where patient-specific dosimetry is used to guide treatments, accurate bone-marrow and whole-body dosimetry will become an essential element of treatment planning. We hope that these guidelines will provide a basis for the optimization and standardization of the treatment of cancer with radiopharmaceuticals, which will facilitate single-and multi-centre radionuclide therapy studies.

KW - Bone marrow

KW - Internal dosimetry

KW - Radionuclide therapy

UR - http://www.scopus.com/inward/record.url?scp=77954886801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954886801&partnerID=8YFLogxK

U2 - 10.1007/s00259-010-1422-4

DO - 10.1007/s00259-010-1422-4

M3 - Article

C2 - 20411259

AN - SCOPUS:77954886801

VL - 37

SP - 1238

EP - 1250

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 6

ER -